Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.45 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.44 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LTB4R | Q15722 | 4/20 | 0.42 |
| ▸ | LTB4R2 | Q9NPC1 | 4/20 | 0.42 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4924887 | 0.89 | HCAR2 (0.48) | HCAR2OPRM1LPAR1LPAR3MEN1 | |
| SCHEMBL4910822 | 0.83 | HCAR2 (0.54) | HCAR2OPRM1LPAR1LPAR3MEN1 | |
| SCHEMBL4910200 | 0.83 | KMT2A (0.43) | HCAR2MEN1KMT2ACTSKPOLB | |
| SCHEMBL1059565 | 0.82 | HCAR2 (0.53) | HCAR2OPRM1LPAR1LPAR3MEN1 | |
| SCHEMBL1059944 | 0.82 | HCAR2 (0.53) | HCAR2OPRM1LPAR1LPAR3MEN1 | |
| SCHEMBL4919039 | 0.80 | PPARG (0.41) | MEN1KMT2ACTSKPOLB | |
| SCHEMBL10638831 | 0.80 | OPRM1 (0.53) | HCAR2OPRM1LPAR1LPAR3MEN1 | |
| SCHEMBL10152007 | 0.78 | HCAR2 (0.54) | HCAR2OPRM1LPAR1LPAR3KMT2A | |
| SCHEMBL12125431 | 0.78 | HCAR2 (0.54) | HCAR2OPRM1LPAR1LPAR3KMT2A | |
| SCHEMBL8290955 | 0.78 | HCAR2 (0.54) | HCAR2OPRM1LPAR1LPAR3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200475-A1 | 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors | PFIZER INC. | 2008-08-21 | — | — | US | disclosed |
| EP-1866317-A1 | 4-PIPERAZINOTHIENO [2, 3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | Pharmacia & Upjohn Company LLC (US) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006103555-A1 | 4-PIPERAZINOTHIENO [2, 3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200475-A1 | 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors | PF4, TBXA2R, P2RY4 | HCAR2 2451/4885OPRM1 1746/4885LPAR1 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.